A Phase I Study of Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Ganetespib (Primary) ; Crizotinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Feb 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 23 Feb 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 10 Jun 2017 Biomarkers information updated